An Integrated DAIDS Laboratory Oversight Framework: Application of the DAIDS GCLP Guidelines.

IF 1.5 4区 医学 Q4 IMMUNOLOGY
AIDS research and human retroviruses Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI:10.1089/AID.2024.0041
Naana Cleland, Nina Kunwar, Usha Sharma, Jamal Dejli, Milton Maciel, Daniella Livnat, Judith Miller, Keith Crawford, Fatima Jones, M Patricia D'Souza
{"title":"An Integrated DAIDS Laboratory Oversight Framework: Application of the DAIDS GCLP Guidelines.","authors":"Naana Cleland, Nina Kunwar, Usha Sharma, Jamal Dejli, Milton Maciel, Daniella Livnat, Judith Miller, Keith Crawford, Fatima Jones, M Patricia D'Souza","doi":"10.1089/AID.2024.0041","DOIUrl":null,"url":null,"abstract":"<p><p>The Division of AIDS (DAIDS) Good Clinical Laboratory Practice (GCLP) Guidelines establish a framework to guide the oversight of laboratories supporting DAIDS-sponsored clinical research or trials. Compliance with these guidelines promotes data reliability, consistency, and validity, and the safety of the clinical research or trial participants and laboratory staff, as well as ensures adherence to regulatory requirements. This article describes the application of the DAIDS GCLP Guidelines, the DAIDS Integrated Laboratory Oversight Framework, and the coordinated efforts of the collaborative oversight team of laboratory experts to support and monitor the performance of over 175 participating laboratories worldwide. Data from two self-administered online surveys conducted in 2017 and 2023 assessed the laboratory staff's experience implementing the GCLP Guidelines. The results of the 2017 survey were instrumental in informing changes to GCLP audit activities and promoting harmonization in the approach to laboratory oversight. A key finding from the 2023 survey results is the preference for hybrid GCLP training, encompassing face-to-face and online modules. Overall, both surveys acknowledged satisfaction with applying and implementing GCLP Guidelines. The need to effectively disseminate information about DAIDS laboratory oversight requirements to support the improved implementation of GCLP Guidelines was notable from both survey results. The collaborative team of laboratory experts and the integrated oversight approach promote knowledge-sharing and accountability to support the application of the GCLP Guidelines and compliance monitoring. The systematic implementation of the integrated laboratory oversight activities helped identify valuable lessons for improving laboratory performance and opportunities to strengthen quality oversight for laboratories participating in clinical research or trials.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"615-621"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/AID.2024.0041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The Division of AIDS (DAIDS) Good Clinical Laboratory Practice (GCLP) Guidelines establish a framework to guide the oversight of laboratories supporting DAIDS-sponsored clinical research or trials. Compliance with these guidelines promotes data reliability, consistency, and validity, and the safety of the clinical research or trial participants and laboratory staff, as well as ensures adherence to regulatory requirements. This article describes the application of the DAIDS GCLP Guidelines, the DAIDS Integrated Laboratory Oversight Framework, and the coordinated efforts of the collaborative oversight team of laboratory experts to support and monitor the performance of over 175 participating laboratories worldwide. Data from two self-administered online surveys conducted in 2017 and 2023 assessed the laboratory staff's experience implementing the GCLP Guidelines. The results of the 2017 survey were instrumental in informing changes to GCLP audit activities and promoting harmonization in the approach to laboratory oversight. A key finding from the 2023 survey results is the preference for hybrid GCLP training, encompassing face-to-face and online modules. Overall, both surveys acknowledged satisfaction with applying and implementing GCLP Guidelines. The need to effectively disseminate information about DAIDS laboratory oversight requirements to support the improved implementation of GCLP Guidelines was notable from both survey results. The collaborative team of laboratory experts and the integrated oversight approach promote knowledge-sharing and accountability to support the application of the GCLP Guidelines and compliance monitoring. The systematic implementation of the integrated laboratory oversight activities helped identify valuable lessons for improving laboratory performance and opportunities to strengthen quality oversight for laboratories participating in clinical research or trials.

DAIDS 实验室综合监督框架:DAIDS GCLP 指南的应用。
艾滋病司(DAIDS)《临床实验室良好操作规范》(GCLP)指南建立了一个框架,指导对支持 DAIDS 赞助的临床研究或试验的实验室进行监督。遵守这些指南可提高数据的可靠性、一致性和有效性,保障临床研究或试验参与者和实验室工作人员的安全,并确保符合监管要求。本文介绍了 DAIDS GCLP 指导方针、DAIDS 综合实验室监督框架的应用情况,以及由实验室专家组成的合作监督团队为支持和监督全球超过 175 家参与实验室的表现而做出的协调努力。2017 年和 2023 年进行的两次自填式在线调查的数据评估了实验室工作人员实施《全球实验室合作计划指南》的经验。2017 年的调查结果有助于为 GCLP 审核活动的变化提供信息,并促进实验室监督方法的统一。2023 年调查结果的一个关键发现是,人们更倾向于接受包括面授和在线模块的混合 GCLP 培训。总体而言,两次调查都对应用和实施 GCLP 指南表示满意。两次调查的结果都表明,需要有效地传播有关 DAIDS 实验室监督要求的信息,以支持更好地实施 GCLP 指导方针。实验室专家合作团队和综合监督方法促进了知识共享和问责制,以支持《全球 协作伙伴关系准则》的应用和合规监测。实验室综合监督活动的系统实施有助于发现宝贵的经验教训,从而提高实验室的绩效,并为参与临床研究或试验的实验室提供加强质量监督的机会。.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
6.70%
发文量
201
审稿时长
3-6 weeks
期刊介绍: AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信